Søgning
Søgning på udtrykket 'remdesivir' giver 24 resultater
Dokumenter [2] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [2]
Dokumenter [2]
Denne vejledning er tiltænkt diagnostik og behandling af COVID-19. Denne retningslinje vil løbende blive opdateret, som ny evidens kommer frem. Ændringer siden version 29: Indikationer for COVID-19 test er tilføjet.
DSI anbefaler fortsat remdesivir ved indlæggelsekrævende COVID-19 med behov for tilskud af ilt, hvor iltmætningen i blodet er under 94% uden ilttilskud hos ellers lungeraske og, at hvor der ved røntgen af thorax påvises infiltrat(er). Dette holdningspapir omhandler baggrunden for anbefalingen.
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?
Clinical Infectious Diseases
29.04.2025
Abstract . Background . There is limited data to support routine remdesivir use in the contemporary era of SARS-CoV-2 with widespread seropositivity.Methods . A restriction of remdesivir among adult immunocompetent patients was implemented across an 8-hospital health system. A pre-post quasi-experimental design was used to compare patients 12 months pre-intervention (June 2022 - May 2023) to 12 months post-intervention (July 2023 – June 2024). The primary outcome was 14-day all-cause mortality.Results …
PLoS One Infectious Diseases
16.04.2025
…ble amount of batch failures and robust product quality attributes. This study was designed to establish a simple, specific, precise, and accurate reverse phase-high performance liquid chromatographic (RP-HPLC) method for the quantitative determination of remdesivir and favipiravir in Capsule dosage forms…
BMC Infectious Diseases
12.04.2025
. Background. Remdesivir (RDV) was the first antiviral approved for mild–to–moderate COVID-19 and for those patients at risk for progression to severe disease after clinical trials supported its association with improved outcomes. Real-world evidence (RWE) generated by artificial intelligence techniques could potentially expedite the validation of new treatments in future health crises…
Journal of Medical Virology
21.03.2025
Journal of Medical Virology, Volume 97, Issue 3, March 2025.
Clinical Infectious Diseases
12.03.2025
Abstract . Background . With progressive accumulation of knowledge on SARS-CoV-2 infection clinical management, treatment guidelines recommended several options including remdesivir (RDV), a broad-spectrum antiviral. Given the evolving nature of COVID-19, capturing the totality of scientific evidence from clinical trials and observational studies is critical to inform clinical decision making…
COVID‐19 Patients Benefitting From Remdesivir for Improved Survival: A Neural Network‐Based Approach
Journal of Medical Virology
11.03.2025
Journal of Medical Virology, Volume 97, Issue 3, March 2025.
BMC Infectious Diseases
6.02.2025
. Abstract. . Background. Early remdesivir administration in high-risk patients with coronavirus disease 2019 (COVID-19) is known to be effective in preventing the progression to severe disease. However, the effect of early remdesivir administration on Omicron variants, which are known to have decreased severity, remains unclear. . . . Methods…
BMC Infectious Diseases
12.01.2025
. Abstract. . Background. Post-COVID condition (PCC) is characterized by persisting symptoms after the resolution of acute COVID-19. Remdesivir (RDV), a broad-spectrum antiviral drug, has been widely used in patients hospitalized with COVID-19 requiring oxygen therapy. We aimed to evaluate the effects of RDV on PCC by assessing patient-reported and functional outcomes. . . …
Antimicrobial Agents And Chemotherapy
20.12.2024
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Antimicrobial Agents And Chemotherapy
8.11.2024
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Antimicrobial Agents And Chemotherapy
8.11.2024
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Clinical Infectious Diseases
25.10.2024
Remdesivir is the only antiviral approved for treatment of persons hospitalized for COVID-19. This supplement presents new information from real-world cohort studies reporting reduced mortality in at-risk populations and reductions in re-admission for COVID-19 in the Omicron era.
Clinical Infectious Diseases
19.10.2024
Abstract . Background . COVID-19 remains a major public health concern, with continued resurgences of cases and substantial risk of mortality for hospitalized patients. Remdesivir has become standard-of-care for hospitalized COVID-19 patients. Given the continued evolution of the disease, clinical management relies on evidence from the current endemic period.Methods …
Clinical Infectious Diseases
16.10.2024
…nts with immunocompromising conditions are at an increased risk for coronavirus disease 2019 (COVID-19)-related hospitalizations and mortality. Randomized clinical trials provide limited enrollment, if any, to inform outcomes of such patients treated with remdesivir.Methods . Using the US PINC AI Healthcare Database, we identified adult patients with immunocompromising conditions, hospitalized for COVID-19 between December 2021 and February 2024…
Clinical Infectious Diseases
16.10.2024
Abstract . Background . Reducing hospital readmission offer potential benefits for patients, providers, payers, and policymakers to improve quality of healthcare, reduce cost, and improve patient experience. We investigated effectiveness of remdesivir in reducing 30-day COVID-19-related readmission during the Omicron era, including older adults and those with underlying immunocompromising conditions.Methods …
Clinical Infectious Diseases
21.09.2024
Clinical Infectious Diseases
21.09.2024
…COVID-19 was unknown. Given the evolution of SARS-CoV-2, real-world data can provide clinicians with updated information. The objective of this analysis was to assess mortality risk in patients hospitalized for COVID-19 during the Omicron period receiving remdesivir+dexamethasone versus dexamethasone alone.Methods …
BMC Infectious Diseases
18.09.2024
. Abstract. . Background. Transaminase and creatinine elevations have been well described in adults treated with remdesivir for COVID-19. It is hypothesized that a similar safety profile exists in children with COVID-19 treated with remdesivir, but available data are limited, especially in children
Antimicrobial Agents And Chemotherapy
7.09.2024
Antimicrobial Agents and Chemotherapy, Ahead of Print.
BMC Infectious Diseases
9.08.2024
. Abstract. . Background. A trial performed among unvaccinated, high-risk outpatients with COVID-19 during the delta period showed remdesivir reduced hospitalization. We used our real-world data platform to determine the effectiveness of remdesivir on reducing 28-day hospitalization among outpatients with mild-moderate COVID-19 during an Omicron period including BQ.1/BQ.1.1/XBB.1.5. . …
Aktuelle smitsomme sygdomme [2]
Aktuelle smitsomme sygdomme [2]
Eurosurveillance latest updates
14.03.2025
…omic Area (EU/EEA) countries. . . Methods. We constructed a literature review compiling 298 publications from four databases: PubMed, Science Direct, LitCovid and BioRxiv/MedRxiv preprint servers. We included publications on nirmatrelvir and ritonavir, remdesivir and tixagevimab and cilgavimab, regdanvimab, casirivimab and imdevimab, and sotrovimab approved by the European Medicines Agency (EMA) by 1 October 2024. . . Results…
ProMED
8.03.2025
…bola vaccine developed by the. International AIDS Vaccine Initiative, a nonprofit vaccine research. organization based in New York City. Officials said today that 264. contacts have been vaccinated so far. The delivery of 2000 doses of. the antiviral drug remdesivir for treatment is ongoing. . Uganda is battling its sixth Ebola Sudan outbreak and its first since. 2022. Ngongo today [6 Mar 2025] emphasized that this is the first to. affect Kampala, the country's capital. . [Byline: Lisa Schnirring] . …